PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its previously announced tender offer (the “Offer”) to acquire all of the outstanding shares of RayzeBio, Inc. (Nasdaq: RYZB) common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired at one minute after 11:59 p.m., Eastern Time, on February 22, 2024 (the “Expiration Time”). Equiniti Trust Company, the depositary for the Offer, has advised that, as of the Expiration Time, appr ...

Bristol Myers (BMY) announced that the FDA has accepted its supplemental new drug application (sNDA) for Krazati (adagrasib) in combination with Erbitux (cetuximab) to treat patients with previously treated KRASG12C-mutated locally advanced or metastatic (la/m) colorectal cancer (CRC). The FDA has assigned the Priority Review status to the company’s sNDA for the combination therapy.A filing designated as a Priority Review reduces the review period by four months. A final decision from the regulatory body is ...

PHILADELPHIA, PENNSYLVANIA - OCTOBER 19: Amanda Poole, Senior Vice President, HR, Bristol Myers ... [+] Squibb speaks on stage during 2023 Pennsylvania Conference For Women at Pennsylvania Convention Center on October 19, 2023 in Philadelphia, Pennsylvania. (Photo by Marla Aufmuth/Getty Images for Pennsylvania Conference For Women)Getty Images for Pennsylvania Conference For WomenBristol Myers Squibb BMY (NYSE: BMY) reported its Q4 results earlier this month, with revenues and earnings beating the street es ...

Picking the best stocks for beginning investors is crucial as they enter the world of long-term investing. With a myriad of options available, it’s essential to focus on stocks that offer growth potential and stability. Despite the short-term market volatility, investing in stocks remains one of the most reliable ways to build wealth over time.In this article, we’ll introduce three stocks for beginning investors that deserve your attention in February 2024. They not only provide a solid foundation for your ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that it has priced a public offering (the “Offering”) of senior unsecured notes in a combined aggregate principal amount of $13 billion (collectively, the “Notes”). The Notes will be issued in nine tranches: (i) $500,000,000 in aggregate principal amount of floating rate notes due 2026, (ii) $1,000,000,000 in aggregate principal amount of 4.950% notes due 2026, (iii) $1,000,000,000 in aggregate principal amount of 4.900% note ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that it recently became aware of an unsolicited “mini-tender” offer by Tutanota LLC (“Tutanota”) to purchase up to five hundred thousand shares of Bristol Myers Squibb’s common stock, representing significantly less than one percent of Bristol Myers Squibb’s common stock outstanding, at an offer price of $55 per share (“Offer Price”). The offer is conditioned on, among other things, the closing price per share of Bristol Mye ...

PALM BEACH, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Recent reports project that the anal cancer market will continue its recent growth through 2030. An article on the MD Anderson website. It said: "More than 8,000 people in the U.S. are diagnosed with anal cancer each year. Due to higher rates of the human papilloma virus, a key risk factor, it affects women more than men. If found early, the disease can be successfully treated. Several types of tumors may be found in the an ...

NEW YORK--(BUSINESS WIRE)--VantAI, a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb (NYSE: BMY), a leading pharmaceutical company, have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest. The partnership leverages VantAI's geometric deep learning capabilities with Bristol Myers Squibb’s expertise in targeted protein degradation to discover and develop new small molecule therapeutics. The collaboration will focus on ...

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. The earnings beat ratio of 79.4% and revenue beat ratio of 85.3% are assuring, though. Combining the actual results with the estimates for the still-to-report companies, the total earnings of the sector are expected to decline 18.2% despite revenue growth of 5.3%.However, many industry bigwigs reported solid results, with some beating on earni ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-K ___________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to _______ Commission File Number 001-01136 ___________________________ BRISTOL-MYERS SQUIBB COMPANY (Exact nam ...